ARTICLE | Finance

For sale or rent

How Vicarius plans to deploy series A to help U.S. biotechs launch drugs in EU

August 18, 2017 8:38 PM UTC

Vicarius Pharma AG is fielding a team of experienced regulatory and commercial executives to give U.S. biotechs an option to retain more of the value of their products in Europe.

On Aug. 14, Vicarius said it raised CHF21 million ($21.8 million) in a series A round from individual investors, including Chairman James Mullen, who is CEO of Patheon N.V. (NYSE:PTHN) and the former CEO of Biogen Inc. (NASDAQ:BIIB)...